[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-diagnosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,55,81,104,128,151,200,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":37,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100450172","avera-cancer-sequencing-and-analytics-protocol-asap-100450172",false,"NCT05142033","Avera Cancer Sequencing and Analytics Protocol (ASAP)","Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)","ASAP","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer\n* Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation\n\nExclusion Criteria:\n\n* Participants incapable of understanding the items listed in the consent form and process\n* Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements","ALL","18 Years",{"count":20,"type":21},25000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.\n\nComprehensive molecular profiling will include somatic tumor testing (tissue and\u002For blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and\u002For whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples.\n\nTo maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research.\n\nData collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.",[25,26,27,28,29,30,31,32,33,34,35,36],"Cancer","Cancer Diagnosis","Early Detection of Cancer","Breast Cancer","Lung Cancer","Colon Cancer","GI Cancer","Gynecologic Cancer","Ovarian Cancer","Endometrial Cancer","CNS Cancer","Hematologic Cancer",[25,38,39,40,41],"Genomics","Genetics","Microbiome","Pharmacogenomics","RECRUITING","2026-03-23",{"date":45,"type":46},"2026-03-27","ACTUAL",{"date":48,"type":46},"2021-11-01",{"date":50,"type":21},"2026-12-31",{"name":52,"class":53},"Avera McKennan Hospital & University Health Center","OTHER",6,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100556343","evaluation-of-multi-cancer-early-detection-testing-in-a-high-risk-military-population-the-sentinel-study-100556343","NCT06523868","Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study","Inclusion Criteria:\n\n* Active-duty or National Guard\u002FReserves military service for four or more years\n* Age ≥ 45\n* Received care at a VA facility within past 5 years\n* Able to sign informed consent\n* Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy\n\nExclusion Criteria:\n\n* Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)\n* Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast\u002Fprostate cancer is acceptable)\n* Individuals in the process of being evaluated for a clinical suspicion of cancer",true,"45 Years",{"count":64,"type":21},1500,"INTERVENTIONAL",[67],"NA","The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty.\n\nThe name of the screening blood test being studied is:\n\n-GRAIL Galleri MCED test",[26],[26],"2026-02-26",{"date":73,"type":46},"2026-02-27",{"date":75,"type":46},"2025-03-31",{"date":77,"type":21},"2028-09-30",{"name":79,"class":53},"Dana-Farber Cancer Institute",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":61,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":65,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":103},"100624967","digital-solutions-for-better-care-100624967","NCT07416513","Digital Solutions for bEtter cAre","ALTHEA: tAckLing menTal Health Cancer Patients and Their Families: Digital Solutions for bEtter cAre","ALTHEA","Inclusion Criteria:\n\nHEALTHCARE PROFESSIONALS:\n\n* Healthcare professionals actually working in oncology and\u002For psychooncology;\n* Teachers of paediatric cancer patients.\n\nADULT POPULATION:\n\n* Patients with a current or previous cancer diagnosis\n* Adequate language proficiency,\n* Able to provide informed consent;\n\nPAEDIATRIC POPULATION:\n\n* Older than 12 years of age;\n* Patients with a current or previous cancer diagnosis;\n* Adequate language proficiency;\n* Legal guardians of paediatric cancer patients able to provide informed consent.\n\nCAREGIVERS:\n\n* Caregivers and\u002For family members of cancer patients who lived or assist the loved ones with a current or previous cancer diagnosis in the cancer journey;\n* Adequate language proficiency;\n* Able to provide informed consent;\n* Caregivers and\u002For family members of paediatric cancer patients under 12 years of age.\n\nExclusion Criteria:\n\n* Healthcare professionals with limited oncology patient contact;\n* Insufficient knowledge of the local language;\n* Severe cognitive impairment, and\u002For mental disorders that prohibited their participation in the study or inadequate verbal skills that may render them incapable of informed consent (as evaluated by the clinician);\n* Inability to understand the study materials (as evaluated by the clinician);\n* Physical or psychological impairment that prohibits their participation in focus groups (as evaluated by the clinician).","12 Years",{"count":91,"type":21},200,[67],"The target population includes cancer patients, caregivers, family members, healthcare providers and mental health specialists, who will be the primary end-users of the Althea platform. For patients, survivors, caregivers, and family members, the sample variables include age, gender, type and stage of disease, and time since the first diagnosis. The healthcare professionals that will be involved in this study are those who attend to oncological patients, with sample variables such as age, gender, professional role, and prior experience and training in oncology or psycho-oncology.",[26],"2026-02-16",{"date":97,"type":46},"2026-02-18",{"date":99,"type":46},"2025-05-14",{"date":50,"type":21},{"name":102,"class":53},"European Institute of Oncology",5,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":61,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":65,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":80},"100622978","the-discover-study-100622978","NCT07390643","The DISCOVER Study","Determining ImpactS of Multi-Cancer Early detectiOn Tests oVER Time in Symptomatic Patients: The DISCOVER Study","DISCOVERY","Inclusion Criteria:\n\n* Be at least 22 years old\n* Have signs and symptoms suggestive of cancer and\u002For have imaging related to signs and symptoms of cancer being evaluated in the Cancer Diagnostic Service clinic\n\nExclusion Criteria:\n\n* Individuals diagnosed with invasive malignancy within 3 years of enrollment\n* Individuals with active cancer requiring active therapeutic intervention at the time of participation (hormone therapy for breast\u002Fprostate cancer is considered acceptable and will not preclude participation)","22 Years",{"count":114,"type":21},100,[67],"The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer.\n\nThe name of the screening blood test being studied is:\n\n-GRAIL Galleri MCED test",[25,26],[25,26],"NOT_YET_RECRUITING","2026-02-02",{"date":122,"type":46},"2026-02-05",{"date":124,"type":21},"2026-07",{"date":126,"type":21},"2028-01-31",{"name":79,"class":53},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":65,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":80},"100554938","stepwise-research-program-to-promote-ingenious-online-supportive-solutions-in-the-relief-of-cancer-related-fatigue-100554938","NCT06505590","STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue","STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue (STEPPING-STONe)","STEPPING-STONe","Inclusion Criteria:\n\n* Age 18 years and older.\n* Having a clinical diagnosis of cancer including patients on active treatment or cancer survivors.\n* Self-reporting moderate to severe CRF for at least one week (worst level of fatigue ≥ 4 on a 10-point numerical rating scale, retained in international guidelines as an optimal cutoff for identifying clinically significant CRF).\n* Being able to read and understand French.\n* Having access to a smartphone.\n* Patients must be affiliated to a social security system or beneficiary of the same.\n\nExclusion Criteria:\n\n* Suffering from current psychiatric disorder or cognitive disorder that would interfere with the ability to consent or participate.\n* Currently engaging in cognitive-behavioral therapy.\n* Currently engaging in another non-drug (behavioral) clinical trial.\n* Suffering from physical related reversible and treatable causes of fatigue (anemia, electrolytes unbalance, infections, renal dysfunction, active metastases causing fatigue, hormonal unbalances (hypothyroidism, adrenal insufficiency, etc.) - according to physician's judgement at the moment of inclusion.",{"count":137,"type":21},372,[67],"Decentralized, randomized hybrid type 2 (effectiveness\u002Fimplementation) controlled trial comparing the effectiveness of three different digital aid modalities programs in reducing the perceived burden of CRF in cancer patients while also gathering data on the implementation strategy.",[26,141],"Moderate or Severe Score of Cancer-related Fatigue (CRF)","2025-09-12",{"date":144,"type":46},"2025-09-15",{"date":146,"type":46},"2025-09-01",{"date":148,"type":21},"2027-11",{"name":150,"class":53},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":61,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":158,"targetDuration":160,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":179,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",{"count":159,"type":21},600,"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[26,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178],"Liver Cancer, Adult","Cancer Screening","Colorectal Cancer (CRC)","Gastric Cancers","Normal Physiology","Pancreatic Cancer, Adult","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Precancerous Conditions","Pancreatitis","Adenoma Colon Polyp","Gastric Ulcer","Oesophagitis","Cirrhoses, Liver",[180,181,164,169,182,183,184,171,185,186,174,187,188,177,189],"Pan-cancer","Deep Learning Models","Colorectal Cancer","Pancreatic Cancer","Gastric Cancer","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":192,"type":46},"2025-04-24",{"date":194,"type":46},"2022-09-01",{"date":196,"type":21},"2025-07-28",{"name":198,"class":53},"Second Affiliated Hospital, School of Medicine, Zhejiang University",4,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100580742","multi-methods-study-on-inclusive-cancer-diagnosis-in-people-with-disabilities-and-health-outcomes-100580742","NCT06841263","Multi-methods Study on Inclusive Cancer Diagnosis in People with Disabilities and Health Outcomes","MICaDO","Inclusion Criteria:\n\nElectronic health record study:\n\n* Patients with psychiatric, intellectual, neurological, and sensory disabilities who received care at San Raffaele Hospital of Milan between 2011 and 2024\n* Patients without disabilities who received care at San Raffaele Hospital of Milan between 2011 and 2024 (ratio 4:1 of patients without vs. with disabilities)\n* Patients with psychiatric, intellectual, neurological, and sensory disabilities recorded in the Lombardy Regional Data Warehouse between 2011 and 2024\n* Patients without disabilities recorded in the Lombardy Regional Data Warehouse between 2011 and 2024 (ratio 4:1 of patients without vs. with disabilities)\n* Patients aged 18 and over\n\nQualitative Interviews:\n\n* Patients aged 18 and over with psychiatric, intellectual, neurological, and sensory disabilities who received care at San Raffaele Hospital of Milan, DAMA (Disabled Advanced Medical Assistance) in Territorial Social Health Companies \"Santi Paolo e Carlo\" and LEDHA (League for the Rights of People with Disabilities and the Promotion of Autonomy) and their caregivers\n* Healthcare provider working at San Raffaele Hospital of Milan, DAMA (Disabled Advanced Medical Assistance) in Territorial Social Health Companies \"Santi Paolo e Carlo\" and general practitioners\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients don't speak the Italian language (for the qualitative study)",{"count":208,"type":21},80,"The MICaDO study is a multi-method study that aims to investigate inclusive cancer diagnosis in people with disabilities and health outcomes. The main objective is to examine variations in cancer diagnosis and outcomes among individuals with psychiatric, intellectual, neurological, and sensory disabilities to develop interventions aimed at improving cancer care. The hypothesis that investigators will investigate is that people with disability are diagnosed with cancer later than people without disability due to a range of barriers, including physical, sensory, cognitive, and social barriers. The study will use a mixed-methods approach, combining quantitative research (electronic health record analysis) and qualitative research (interviews). The total duration of the study is two years.",[211,26],"Disabled Persons","2025-03-17",{"date":214,"type":46},"2025-03-20",{"date":216,"type":21},"2025-04-01",{"date":218,"type":21},"2027-03-31",{"name":220,"class":53},"Cristina Renzi",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":61,"sex":17,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":65,"phases":231,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":80},"100565708","phase-2-hyperpolarized-mr-imaging-with-carbon-13-pyruvate-in-the-human-body-100565708","NCT06645691","Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body","POLARIC-13","Inclusion Criteria:\n\nHealthy Volunteers:\n\n1. Age 21 years and above\n2. No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)\n3. No history of cancer\n4. Able and willing to comply with study procedures and provide signed informed consent\n\nPatients with cardiovascular\u002Fcardiometabolic diseases:\n\n1. Age 21 years and above\n2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stable heart failure; and\u002For\n3. Cardiometabolic conditions (such as diabetes on medications, hypertension, central obesity, fatty liver disease)\n4. Able and willing to comply with study procedures and provide signed informed consent\n\nExclusion Criteria:\n\n1. Standard contraindications for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)\n2. Unstable medical conditions (such as symptomatic heart failure, unstable hypertension\u002Fglucose levels as determined by investigators, symptomatic arrhythmias, angina)\n3. Pregnant or nursing women\n4. Known allergies to pyruvate or any of its components","21 Years","99 Years",{"count":91,"type":21},[232],"PHASE2","Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and\u002For cardiometabolic diseases.",[235,236,26,237,238],"Heart Failure","Cardiometabolic Syndrome","Cardiovascular Diseases","Healthy Volunteers",[240,241,242,243,244,245],"Carbon-13 Pyruvate","Magnetic Resonance Imaging","Lactate","Alanine","Bicarbonate","Hyperpolarized Pyruvate (13C) Injection","2024-12-03",{"date":248,"type":46},"2024-12-06",{"date":250,"type":46},"2024-10-17",{"date":252,"type":21},"2028-05-31",{"name":254,"class":53},"National Heart Centre Singapore"]